Skip to main content

Table 1 Characteristics of all surgical patients

From: Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases

Variable   Synchronous disease (n = 34) Metachronous disease (n = 38) Conversion disease (n = 16) p
Age, yearsa   67.5 (35–85) 63 (35–88) 57.5 (32–80) 0.0458
Sex, n (%)      
  Male 22 (64.7 %) 20 (52.6 %) 8 (50 %) 0.487
  Female 12 (35.3 %) 18 (47.4 %) 8 (50 %)  
T, n (%)      
  T1/2 1 (2.9 %) 3 (7.9 %) 0 (0 %) 0.377
  T3/4 33 (97.1 %) 35 (92.1 %) 16 (100 %)  
N, n (%)      
  N 13 (38.2 %) 19 (50 %) 7 (43.8 %) 0.603
  N+ 21 (61.8 %) 19 (50 %) 9 (56.3 %)  
Location of primary tumor, n (%)      
  Colon 22 (64.7 %) 23 (60.5 %) 12 (75 %) 0.596
  Rectum 12 (35.3 %) 15 (39.5 %) 4 (25 %)  
Preoperative chemotherapy, n (%)      
  Yes 5 (14.7 %) 10 (26.3 %) 16 (100 %) <0.0001
  No 29 (85.3 %) 28 (73.7 %) 0 (0 %)  
Adjuvant chemotherapy, n (%)      
  Yes 16 (47.1 %) 7 (18.4 %) 7 (43.8 %) 0.0252
  No 18 (52.9 %) 31 (81.6 %) 9 (56.3 %)  
No. of liver metastases, n (%)      
  1 10 (29.4 %) 22 (57.9 %) 1 (6.3 %) <0.0001
  2–4 15 (44.1 %) 10 (26.3 %) 2 (12.5 %)  
  ≥5 9 (26.5 %) 6 (15.8 %) 13 (81.3 %)  
Size, n (%)      
  0–5 cm 28 (82.4 %) 35 (92.1 %) 11 (68.8 %) 0.0946
  >5 cm 6 (17.6 %) 3 (7.9 %) 5 (31.3 %)  
Resection, n (%)      
  0 31 (81.6 %) 38 (100 %) 9 (56.3 %) <0.0001
  1 3 (18.4 %) 0 (0 %) 7 (43.8 %)  
CEA (ng/mL)a   17.9 (2.1–2300) 12.45 (1.6–196.3) 11.35 (2.4–7510) 0.729
CA19-9 (U/mL)a   19.45 (2–7676) 19.8 (2–7191) 27.3 (2–1063) 0.78
  1. aMedian (range)